Gynecological Oncology Surgery During COVID-19 Pandemic: What We Should Know

DOI: https://doi.org/10.22502/jlmc.v8i1.357
Keywords: COVID 19, Oncology surgery

Abstract

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) that causes Corona Virus Disease -19 (COVID-19) is a novel virus and hence humans do not have any prior immunity to it. Every human being is susceptible to this viral infection and rapid spread worldwide made WHO declare it as a global pandemic. Cancer patients are even more vulnerable not only because they are immunocompromised by the disease process itself, but also due to potential effect of chemotherapy, radiotherapy along with substantial effect on their timing of treatment. Patients older than 65 years, and those with preexisting co-morbidities are considered more at
risk. Considering the increased chances of intensive care unit admission, need of mechanical ventilation and possible mortality, all cancer patients should be educated about preventive measures, personal protection, social distancing and isolation. Another possible impact of COVID-19 could be delays in initial evaluation, diagnosis and initiation of actual treatment which are independent risk factors for cancer related mortality. This is due to limited services provided at the health care facilities, lockdown effects, fear of being infected
and economic crisis.

Downloads

Download data is not yet available.

Author Biography

Suresh Kayastha, Kathmandu Cancer Center, and Nepal Korea Friendship Municipality Hospital, Nepal.

Consultant Gynecologic oncologist

References

Biswas A, Bhattacharjee U, Chakrabarti AK, Tewari DN, Banu H, Dutta S. Emergence of Novel Coronavirus and COVID-19: whether to stay or die out? Crit Rev Microbiol. 2020;46(2):182- 193. PMID: 32282268 DOI: https://doi.org.10.1080/1040841X.2020.1739001

World Health Organization. WHO announces COVID-19 outbreak a pandemic. 2020 Mar 12. Available from: http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic

ESMO Guidelines, Cancer Patient Management during the COVID-19 Pandemic, ESMO Management and Treatment Adapted Recommendations in the Covid-19 Era: Endometrial Cancer. Available from: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/gynaecological-malignancies-endometrial-cancer-in-the-covid-19-era.

ESMO Guidelines, Cancer Patient Management during the COVID-19 Pandemic, ESMO Management and Treatment Adapted Recommendations in the Covid-19 Era: Cervical cancer. Available from: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/gynaecological-malignancies-cervical-cancer-in-the-covid-19-era

ESMO Guidelines, Cancer Patient Management during the COVID-19 Pandemic, ESMO Management and Treatment Adapted Recommendations in the Covid-19 Era: Ovarian cancer. Available from: https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/gynaecological-malignancies-epithelial-ovarian-cancer-in-the-covid-19-era.

Bhatla N, Singhal S. The COVID-19 Pandemic and Implications for Gynaecologic Cancer Care. Indian J Gynecol Oncolog. 2020;18(2):48. DOI: https://doi.org/10.1007/s40944-020-00395-7

Lavoué V, Akladios C, Gladieff L, Classe JM, Lécuru F, Collinet P. Onco-gynecologic surgery in the COVID-19 era: Risks and precautions-A position paper from FRANCOGYN, SCGP, SFCO, and SFOG. J Gynecol Obstet Hum Reprod. 2020;101787 [Epub ahead of print]. PMID: 32407899 DOI: https://doi.org/10.1016/j.jogoh.2020.101787

Ramirez PT, Chiva L, Eriksson AGZ, Frumovitz M, Fagotti A, Martin AG, et al.COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers. International Journal of Gynecologic Cancer. 2020; [Epub ahead of print]. DOI: https://doi.org/10.1136/ijgc-2020-001419

British gynecological cancer society. BGCS framework for care of patients with gynaecological cancer during the COVID-19 Pandemic. Available from: https://www.bgcs.org.uk/wp-content/uploads/2020/03/BGCS-covid-guidance-v1.-22.03.2020.pdf

Society of gynecologic oncology. Gynecologic Oncology Considerations during the COVID-19 Pandemic. Available from: https://www.sgo.org/clinical-practice/management/covid-19-resources-for-health-care-practitioners/gyn-onc-considerations-during-covid-19/

Thomakos N, Pandraklakis A, Bisch SP, Rodolakis A, Nelson G, et al. ERAS protocols in gynecologic oncology during covid-19 pandemic. International Journal of Gynecologic Cancer. 2020; [Epub ahead of print]. DOI: https://doi.org/10.1136/ijgc-2020-001439

Published
2020-05-30
How to Cite
1.
Kayastha S. Gynecological Oncology Surgery During COVID-19 Pandemic: What We Should Know. J Lumbini Med Coll [Internet]. 30May2020 [cited 14Jan.2025];8(1):142-4. Available from: https://jlmc.edu.np/index.php/JLMC/article/view/357
Issue
Vol 8 No 1 (2020): vol:8, No:1
Section
Perspective

Copyright (c) 2020 Suresh Kayastha

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

  • The Journal of Lumbini Medical College (JLMC) publishes open access articles under the terms of the Creative Commons Attribution (CC BY) License which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
  • JLMC requires an exclusive licence to publish the article first in its journal in print and online.
  • The corresponding author should read and agree to the following statement before submission of the manuscript for publication,
    • License agreement
    • In submitting an article to Journal of Lumbini Medical College (JLMC) I certify that:
      1. I am authorized by my co-authors to enter into these arrangements.
      2. I warrant, on behalf of myself and my co-authors, that:
        1. the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights;
        2. I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to JLMC are not in breach of any other obligation;
        3. the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy;
        4. I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will not, if followed accurately, cause any injury, illness or damage to the user.
      3. I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0. If the law requires that the article be published in the public domain, I/we will notify JLMC at the time of submission, and in such cases the article shall be released under the Creative Commons 1.0 Public Domain Dedication waiver. For the avoidance of doubt it is stated that sections 1 and 2 of this license agreement shall apply and prevail regardless of whether the article is published under Creative Commons Attribution License 4.0 or the Creative Commons 1.0 Public Domain Dedication waiver.
      4. I, and all co-authors, agree that, if the article is editorially accepted for publication in JLMC, data included in the article shall be made available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated. For the avoidance of doubt it is stated that sections 1, 2, and 3 of this license agreement shall apply and prevail.

                            Please visit Creative Commons web page for details of the terms.